Diagnostic accuracy of Loopamp Trypanosoma brucei detection kit for diagnosis of human African trypanosomiasis in clinical samples by Mitashi, P. et al.
Diagnostic Accuracy of Loopamp Trypanosoma brucei
Detection Kit for Diagnosis of Human African
Trypanosomiasis in Clinical Samples
Patrick Mitashi1,2,3, Epco Hasker1, Dieudonne´ Mumba Ngoyi2,3, Pati Patient Pyana3, Veerle Lejon1,
Wim Van der Veken4, Pascal Lutumba2,3, Philippe Bu¨scher1, Marleen Boelaert1, Stijn Deborggraeve1*
1 Institute of Tropical Medicine, Antwerp, Belgium, 2 Faculty of Medicine, Kinshasa University, Kinshasa, Democratic Republic of the Congo, 3 Institut National de
Recherche Biome´dicale, Kinshasa, Democratic Republic of the Congo, 4 Belgian Development Agency, Kinshasa, Democratic Republic of the Congo
Abstract
Background: Molecular methods have great potential for sensitive parasite detection in the diagnosis of human African
trypanosomiasis (HAT), but the requirements in terms of laboratory infrastructure limit their use to reference centres. A
recently developed assay detects the Trypanozoon repetitive insertion mobile element (RIME) DNA under isothermal
amplification conditions and has been transformed into a ready-to-use kit format, the Loopamp Trypanosoma brucei. In this
study, we have evaluated the diagnostic performance of the Loopamp Trypanosoma brucei assay (hereafter called LAMP) in
confirmed T.b. gambiense HAT patients, HAT suspects and healthy endemic controls from the Democratic Republic of the
Congo (DRC).
Methodology/Principal findings: 142 T.b. gambiense HAT patients, 111 healthy endemic controls and 97 HAT suspects with
unconfirmed status were included in this retrospective evaluation. Reference standard tests were parasite detection in
blood, lymph or cerebrospinal fluid. Archived DNA from blood of all study participants was analysed in duplicate with LAMP.
Sensitivity of LAMP in parasitologically confirmed cases was 87.3% (95% CI 80.9–91.8%) in the first run and 93.0% (95% CI
87.5–96.1%) in the second run. Specificity in healthy controls was 92.8% (95% CI 86.4–96.3%) in the first run and 96.4% (95%
CI 91.1–98.6%) in the second run. Reproducibility was excellent with a kappa value of 0.81.
Conclusions/Significance: In this laboratory-based study, the Loopamp Trypanosoma brucei Detection Kit showed good
diagnostic accuracy and excellent reproducibility. Further studies are needed to assess the feasibility of its routine use for
diagnosis of HAT under field conditions.
Citation: Mitashi P, Hasker E, Ngoyi DM, Pyana PP, Lejon V, et al. (2013) Diagnostic Accuracy of Loopamp Trypanosoma brucei Detection Kit for Diagnosis of
Human African Trypanosomiasis in Clinical Samples. PLoS Negl Trop Dis 7(10): e2504. doi:10.1371/journal.pntd.0002504
Editor: Joseph Mathu Ndung’u, Foundation for Innovative New Diagnostics (FIND), Switzerland
Received May 30, 2013; Accepted September 11, 2013; Published October 17, 2013
Copyright:  2013 Mitashi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: FIND, the sponsor of the development of the LAMP kit, provided the required kits and reagents for this study. The views expressed by the authors do
not necessarily reflect the views of the funding agency. The biological specimens were collected in collaboration with the National Human African
Trypanosomiasis Control Program (PNLTHA) of the D.R. Congo, in a study financed by the Secondary Research Funding of the Institute of Tropical Medicine (HAT
PolyB) and a study financed by the Belgian Directorate General for Development Cooperation. PM and PPP received a PhD grant and DMN received a Post-Doc
grant from the Belgian Directorate General for Development Cooperation. The funders had no role in study design, data collection and analysis, decision to
publish or preparation of the manuscript.
Competing Interests: I have read the journal’s policy and have the following conflicts: FIND, the sponsor of the development of the LAMP kit, made useful
suggestions on the technical protocol and provided the required kits and reagents for this study. The funders had no role in study design, data collection and
analysis, decision to publish or preparation of the manuscript. This does not alter our adherence to all PLOS policies on sharing data and materials.
* E-mail: sdeborggraeve@itg.be
Introduction
Human African trypanosomiasis (HAT) is a protozoan disease
caused by the Trypanosoma brucei species, which are cyclically
transmitted by tsetse flies. Two subspecies are pathogenic to man:
Trypanosoma brucei (T.b.) gambiense in central and western Africa,
and Trypanosoma brucei rhodesiense in east and southern Africa [1].
Currently, less than 10 000 cases per year are reported by the
World Health Organization, of which over 70% occur in the
Democratic Republic of Congo (DRC) [2].
Diagnostic algorithms for T.b. gambiense HAT generally start
using the Card Agglutination Test for Trypanosomiasis (CATT) as
initial screening for the presence of antibodies. Those testing
positive in CATT are then subjected to parasitological tests for
confirmation of the infection [3]. Parasitological confirmation
relies on the microscopic search for parasites either in lymph,
blood or cerebrospinal fluid (CSF). The most sensitive method is
based on the mini-anion exchange centrifugation technique
(mAECT), yielding an analytical sensitivity of ,50 parasites per
mL of blood [4,5]. However, given the low parasitemia associated
with T.b. gambiense infection, some truly infected individuals
remain negative in the mAECT.
Because of the limited sensitivity of parasitological confirmation
tests, molecular methods have been developed [6,7] and they
generally show high sensitivity and specificity [7]. They can be
performed on various specimen types such as whole blood, blood
stored on filter paper and CSF. However, the need for labora-
tory instruments for nucleic acid extraction, amplification and
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visualization are obstacles to their application in clinical settings in
HAT endemic areas [8]. Isothermal reactions such as nucleic acid
sequence-based amplification (NASBA) and loop mediated
isothermal amplification (LAMP) have recently been developed
for the diagnosis of HAT [7,9]. In contrast to PCR, they do not
require thermocyclers and amplification can be conducted in a
heating block or a hot water bath. A potential advantage of
NASBA is that it targets RNA and thus might have greater utility
as a test of cure compared with DNA-targeting molecular tests [6].
However, NASBA is not yet ready to be used under field
conditions due to the complexity of RNA purification [6]. Instead
of RNA, LAMP amplifies DNA that is less prone to damage
during transport and storage of samples and during extraction.
Sets of specific inner and outer primers are needed for autocycling
strand displacement DNA synthesis by the Bst DNA polymerase at
a temperature between 60–65uC. The results can be interpreted
by several detection formats, such as turbidity, fluorescent DNA
intercalating dyes, fluorescent hybridisation probes and oligochro-
matography [9,10].
There are published reports on two LAMP assays for
Trypanozoon DNA. One assay targets the single copy paraflagellar
rod protein A (PfrA) gene and the second is based on the repetitive
insertion mobile element (RIME) [9]. Recently, the latter has been
transformed into a commercially available kit, the Loopamp
Trypanosoma brucei kit (Eiken Chemical Co LTD, Japan in
collaboration with FIND, Geneva, Switzerland) [9]. Ready-to-
use reaction tubes are provided with the reagents dried down in
the caps of the tubes, together with negative and positive controls.
LAMP showed great promise with purified DNA and with
trypanosome-spiked blood but has not been yet evaluated on
specimens from HAT patients and controls. We here present the
data from the first diagnostic evaluation of the commercial LAMP
kit on DNA extracted from blood of 142 gambiense HAT patients,
97 gambiense HAT suspects and 111 healthy endemic controls from
the DRC.
Methods
Ethical clearance
All samples analysed in this study were collected within the
framework of two earlier diagnostic studies for HAT, PARAHAT
and HAT-PolyB. Both studies were approved by the ethical
committees of the University Hospital in Antwerp (registration
numbers ITG09415684 and B30020108363, respectively) and the
Ministry of Health of the D.R Congo (registration numbers M-D/
226/2010 and M-D/179/2010, respectively). The ethical com-
mittees approved extended use of the samples in further HAT
diagnostic studies. Written informed consent was obtained from all
study participants and all samples were anonymized.
Characteristics of study samples
For this retrospective evaluation we used DNA extracts from
blood of study participants recruited consecutively in 2010 in
Bandundu, the most HAT endemic province in DRC [11]. From
all participants testing positive on CATT whole blood, the CATT
was repeated with sequential plasma dilutions and the end titer
was recorded [3]. For diagnostic purposes all were subjected to
parasitological confirmation, irrespective of CATT results. Try-
panosomes were detected by examination of lymph node aspirate
(in subjects with swollen cervical nodes) or by blood examination
(all study subjects) with the capillary centrifugation technique
(CTC) [12], mAECT on whole blood [8], and mAECT on buffy
coat [5]. For patients with parasites detected in the lymph or
blood, or with a plasma CATT end titer $1:8 a lumbar puncture
was done. Parasite detection in CSF was performed with the single
modified centrifugation technique [4]. DNA was extracted from
blood with the MaxwellH 16 Blood DNA Purification robot
(Promega Corporation, Madison, WI,USA) from 200 mL blood
stabilised in an equal volume of DNA stabilising GE buffer (6 M
guanidium, 0.2 M EDTA, pH=7.5). Final DNA extraction
volumes were 300 mL and extracts were stored at 220uC. Time
between DNA extraction and LAMP testing was 1.5 to 2 years. All
blood samples were also analysed with a Trypanozoon-specific 18S
rDNA PCR in duplicate [13]. This PCR amplifies a 120 bp DNA
sequence of the Trypanozoon 18S rRNA gene and the amplified
product is visualized using conventional electrophoresis in agarose
gels and ethidium bromide staining. All PCR testing was done in
duplicate at the Institute of Tropical Medicine in Antwerp.
Participants were considered as HAT patients if parasites were
detected by any parasitological method in any blood or lymph or
CSF sample. Healthy endemic controls were recruited during
active screening in the villages [14]. Healthy endemic controls are
individuals presenting themselves for CATT screening but with no
clinical symptoms of HAT, no previous history of HAT and
negative results in CATT whole blood, trypanolysis and mAECT.
Individuals with suggestive clinical findings, a positive CATT (cut-
off titer $1:4) and positive trypanolysis test that were not
confirmed as cases on parasitological testing and who had no
previous history of HAT, were classified as HAT suspects.
Altogether, frozen DNA from blood of 350 study participants
were tested by LAMP: 142 from confirmed HAT patients, 97 from
HAT suspects and 111 from healthy endemic controls. In the
confirmed HAT patient group, standard tests showed parasites in
the blood in 131 cases while in 5 and 6 cases parasites were only
found in the CSF and lymph respectively.
Index test: Loopamp Trypanosoma brucei Detection Kit
The Loopamp Trypanosoma brucei Detection Kit (Eiken Chemi-
cal,Taito-ku, Tokyo, Japan) was applied in duplicate on the DNA
extracts by one of the authors (PM), a trained clinical microbi-
ologist, who was blinded to the disease status of the samples. The
test was performed at ITM Antwerp according to the product
insert. Briefly, the dried reagents in the tube were reconstituted in
a 25 ml reaction solution, containing 3 ml template DNA and 22 ml
negative control buffer, and immediately placed in the LAMP
Author Summary
Diagnosis and effective treatment are cornerstones in the
control of human African trypanosomiasis (HAT). Molecular
tools such as the polymerase chain reaction (PCR) detect
the parasite’s DNA and are generally very sensitive and
specific. However, PCR is not applicable in field settings
because it requires a laboratory infrastructure and sophis-
ticated equipment. A recently developed loop-mediated
isothermal amplification (LAMP) has emerged as a simpler
alternative to conventional molecular methods for the
diagnosis of HAT. The test has been transformed into a
diagnostic kit for qualitative detection of the parasite’s
DNA in clinical specimens, the Loopamp Trypanosoma
brucei Detection Kit. In this study, we evaluated this kit in
laboratory conditions on DNA extracted from blood
samples of 142 patients, 97 suspects and 111 healthy
endemic controls in the Democratic Republic of the
Congo. The test showed good diagnostic accuracy and
excellent reproducibility. Given the practical advantages of
LAMP over conventional nucleic acid methods these are
promising results. Further studies are needed to assess the
test’s accuracy and feasibility in field conditions.
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incubator (LF-160 incubator, Eiken Chemical co,Taito-ku, Tokyo,
Japan). LAMP amplified Trypanosoma brucei DNA was visualised
using the provided UV-LED device. Amplified DNA emits green
fluorescence while there is no fluorescence in negative samples.
The provided positive and negative controls were taken in each
run (14 tests) to validate the test results.
Data analysis
Sensitivity and specificity values and their 95% confidence
intervals were calculated for the LAMP in the confirmed HAT
patients and in healthy endemic controls, respectively. The
sensitivity was defined as the proportion of confirmed HAT
patients who are positive by the index tests and specificity as the
proportion of healthy endemic controls who are negative by the
index test. Each DNA extract was tested in duplicate by LAMP.
Agreement between LAMP and PCR and reproducibility of
LAMP were assessed on all specimens (patients, suspects, controls)
with Cohen’s Kappa and interpreted following the grading system
described by Landis and Koch (1977) [15]. Data were analysed in
Stata, version 11.1 (StataCorp, College Station, Lakeway, Texas,
USA).
Results
Diagnostic accuracy
Of the 142 HAT patients, 132 and 124 were LAMP positive
in respectively the first and second run, corresponding with
sensitivities of 93.0% (95% CI: 87.5%–96.1%) and 87.3% (95%
CI : 80.9–91.8), respectively (table 1). Of the 11 patients with
trypanosomes detected only in lymph or in CSF, 7 were positive in
both LAMP runs on blood. Of the 97 HAT suspects, 6 were
positive in both replicates of LAMP, 8 and 20 were positive in the
first and second replicate, respectively. Of 111 healthy endemic
controls, 4 tested positive twice with LAMP and 4 tested positive
only once. Specificity estimates range from 92.8% (95% CI 86.4–
96.3%) to 96.4% (95% CI 91.1%–98.6%). Sensitivities and
specificities of PCR were in the same range as LAMP with
overlapping confidence intervals (table 1).
Agreement between molecular methods
Assessed on all participants (patients, suspects and healthy
controls), agreement between the two LAMP replicates was
excellent with a kappa value of 0.81 (95% CI: 0.71–0.92)
(table 2), which is in the same range as the PCR replicates (kappa
value = 0.82, 95% CI: 0.72–0.92). Agreement between the first
replicate of LAMP and the 18S PCR was also excellent with a
kappa value of 0.82 (95% CI: 0.72–0.93). Kappa values of LAMP
replicates were lower in the subgroups but in the same range as for
PCR and with overlapping confidence intervals (table 2).
Discussion
In this diagnostic accuracy study, the LAMP showed a
sensitivity of 87.3% and 93.0% in the two testing runs. Specificity
was 92.8% and 96.4%, with a lowest lower limit of the 95%
confidence interval of 86.4%. Agreement between LAMP
replicates as well as between LAMP and PCR was excellent with
kappa values above 0.8.
The sensitivity of the commercial LAMP kit tested here was
equivalent to that of the 18S PCR test, which showed a sensitivity
between 87.3% (95% CI: 80.9–91.8) and 90.1% (95% CI: 84.1–
94.0) on the same DNA extracts. This is in line with the
observation that both tests showed identical analytical sensitivities
of 100 parasites per mL of blood in a head-to-head comparison
using experimentally prepared blood samples (data not shown).
While the LAMP detects the RIME DNA elements (500 copies per
haploid genome) [16], the PCR targets the 18S rRNA gene (10–
100 copies) [17]. In the 11 confirmed HAT patients with parasites
only detected in the lymph or CSF, 7 were positive in both LAMP
runs. In contrast, we also observed 5 false negative LAMP results
in mAECT positive patients. In the HAT suspects, who could not
be confirmed by the parasitological methods, we observed
particularly poor agreement between the two LAMP repetitions
(kappa= 0.35). These discordances are probably due to the fact
that the target DNA concentration in such samples is at the
detection limit of the test. If LAMP is to be used to confirm non-
confirmed HAT suspects, testing multiple samples from the same
patient may increase its sensitivity.
The specificity of the LAMP kit was in the same range as the
18S PCR, which showed a specificity between 96.4% (95% CI
91.1–98.6%) and 97.3% (95% CI 92.3–99.1%) on the same
samples. The LAMP was twice positive in 4 of the 111 healthy
endemic controls. Three of these LAMP positive controls were at
least one time also positive by PCR. Some positive healthy
endemic controls may actually be infected with T.b. gambiense
because the parasitological confirmation algorithm using mAECT
is not 100% sensitive, and this may lead to an underestimation of
the specificity of the index tests. Another possible reason may be
the absence of the LiTat 1.3 variable surface glycoprotein (VSG),
which is the antigen used in the CATT and the trypanolysis test, in
some strains of T.b. gambiense [18,19]. In addition, low antibody
titers may be present in early or latent infections [20]. However,
false positive LAMP results due to non-specific amplification
reactions cannot be excluded. Since the LAMP detects the RIME
DNA of all Trypanozoon, a transient human infection with T.b. brucei
could also have led to a positive test result [21]. The recently
developed LAMP assay that targets the T.b. gambiense specific
glycoprotein (TgsGP) gene [16] can exclude an infection with
other Trypanozoon and thus may be more specific. However, in the
Table 1. Sensitivities and specificities of replicate RIME LAMP and 18S PCR on the blood of HAT patients and healthy endemic
controls.
HAT patients (n =142) Healthy endemic controls (n =111)
Test Positive results Sensitivity% (95% CI) Positive results Specificity% (95% CI)
LAMP Run 1 132 93.0 (87.5–96.1) 4 96.4 (91.1–98.6)
Run 2 124 87.3 (80.9–91.8) 8 92.8 (86.4–96.3)
PCR Run 1 124 87.3 (80.9–91.8) 4 96.4 (91.1–98.6)
Run 2 128 90.1 (84.1–94.0) 3 97.3 (92.3–99.0)
Note. n: number of specimens, CI: confidence interval.
doi:10.1371/journal.pntd.0002504.t001
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same publication the authors showed that the diagnostic sensitivity
of the TgsGP LAMP is lower than the sensitivity of the RIME
LAMP.
Reproducibility of LAMP was excellent and as good as that of
PCR, with kappa values of 0.81 and 0.82 respectively when all
samples were considered. Within the sub groups lower kappa
values were observed, which is due to the fact that in these more
homogenous groups the expected agreements were much higher.
Values observed within the groups were in the same ranges for
LAMP and PCR. The LAMP-amplified DNA is visualised by a
UV-LED device attached to the LF-160 incubator. This single-
tube and easy read-out avoids the risk for sample contamination
due to post-amplification manipulations. Another advantage is
that Loopamp Trypanosoma brucei Detection Kit is thermostable at
30uC which greatly enhances the feasibility of use in peripheral
health facilities in tropical countries. Although in the present study
LAMP was performed on DNA extracted with the MaxwellH
DNA Purification robot, simplified DNA extraction methods that
are compatible with LAMP are currently under development. The
requirement of electrical power supply to operate the incubator for
the amplification step constitutes a potential drawback for use in
remote health facilities, even if it can be circumvented by using an
alternative power source such as an electrical generator and/or a
photovoltaic panel.
In recent years there has been a sharp decline in HAT
prevalence in most of the endemic countries and the classical case
finding approach by mobile screening units is becoming less cost-
effective. There is thus an urgent need to consider alternative ways
of surveillance and case detection, and the LAMP technology
could play a role [22]. Though still more complicated than the
parasitological methods, LAMP is feasible for use at the level of a
district hospital laboratory and could be useful as part of a testing
algorithm for samples collected at more peripheral levels. LAMP
can be applied on samples collected elsewhere without the need to
be processed the same day. Either CATT or one of the newly
developed rapid tests [23] can be used to screen suspects for HAT
at health center or at village level; LAMP can then be used in a
more centrally located laboratory as a second step in the diagnostic
algorithm. LAMP data for serologically positive individuals who
remained negative in parasitological testing may be particularly
informative. However, future research should determine if HAT
suspects with positive LAMP testing need further diagnostic work-
up before being put on treatment and if the detection of LAMP
positive individuals from the same geographical origin should be a
trigger for intensified surveillance efforts. Although we feel that
LAMP is best suited for use in central laboratories, the feasibility
and cost-effectiveness of including LAMP in the screening process
by the mobile teams may be determined in specific evaluation
studies but should also take into account the test specimen
preparation prior to the LAMP itself.
In conclusion, the study shows that the LAMP has similar
diagnostic accuracy as the 18S rDNA PCR and can replace PCR
for accurate and simplified detection of Trypanozoon DNA in
clinical specimens. LAMP may have an important role to play in
disease surveillance. However, one should note that the specificity
of LAMP is not 100%, that HAT treatment is complex and toxic,
and that the positive predictive value of tests in low incidence
settings is low. Based on this study we cannot yet recommend
initiating treatment of patients based on LAMP results; further
evidence from prospective clinical studies under field conditions is
needed, as well as cost-effectiveness analysis of competing
algorithms. Feasibility studies of LAMP are currently conducted
in the D.R. Congo (http://www.finddiagnostics.org/programs/
hat-ond/hat/molecular_diagnosis.html).
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